Healthcare Services Coverage

A concussion is a type of traumatic brain injury (TBI) that occurs when the brain experiences a sudden jolt or blow to the head or body, causing the brain to move rapidly back and forth within the skull. This medical condition can temporarily impair brain function and disrupt normal neurological processes. The main types of concussion assessments are diagnosis and treatment. Diagnosis is the identification of a medical condition or disease based on an evaluation of symptoms, medical history, and diagnostic tests. They are diagnosed using various devices, such as imaging devices, magnetic resonance imaging (MRI) devices, X-rays, computed tomography, monitoring devices, and others. They are used by various end-users, such as hospitals and clinics, diagnostic centers, medical camps, and others. The global concussion market is segmented - 1) By Assessment: Diagnosis, Treatment 2) By Device: Imaging Devices, Magnetic Resonance Imaging (MRI) Devices, X-Ray, Computed Tomography, Monitoring Devices, Other Devices 3) By End User: Hospitals And Clinics, Diagnostic Centers, Medical Camps, Other End-Users The global concussion market size is expected to grow from $7.39 billion in 2022 to $7.63 billion in 2023 at a compound annual growth rate (CAGR) of 3.34%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of concussion market is expected to reach $8.82 billion in 2027 at a CAGR of 3.68%. The increase in the prevalence of brain injuries is expected to propel the growth of the concussion market going forward. Brain injuries refer to any type of injury or damage that affects the brain, resulting in a wide range of physical, cognitive, and emotional impairments. Treating concussions early and properly can help to reduce the effects of brain-related injuries on an individual's general brain health through physical and cognitive rest, symptom management, and gradual return to activities. Additionally, rising traffic accidents have also increased the occurrence of brain injuries. For instance, in January 2023, according to the article published by the NCBI (National Center for Biotechnology Information) a US-based agency for biomedical and genomic information, every year in the United States, an estimated 1.7 million people experience traumatic brain injuries, with 15 to 19-year-olds and seniors 65 and older having the highest risk of suffering one. For instance, in March 2023, according to the American Society of Clinical Oncology, in the US, primary malignant tumors of the brain and spinal cord are expected to affect 24,810 people (14,280 men and 10,530 women) in 2020. Further, brain tumors make up 85% to 90% of all cases. Therefore, the increase in the prevalence of brain injuries is driving the growth of the concussion market. Major players in the concussion market are Pfizer Inc., Novartis AG, Sanofi SA, Abbott Laboratories, Medtronic plc, Viatris Inc., Zydus Lifesciences Ltd., Integra LifeSciences Corporation, Nihon Kohden Corporation, Raumedic AG, Lupin Limited, NeuroPace Inc., Compumedics Limited, NeuroLogica Corporation, Neural Analytics Inc., NovaSignal Corp., Back Bay Life Science Advisors, BrainScope Company Inc., Neuro Kinetics Inc., ImPACT Applications Inc., NanoDx, Inc., Neuren Pharmaceuticals Limited, Advanced Brain Monitoring Inc., ElMindA Ltd., NeurOptics Inc., InfraScan Inc., Neuro Assessment Systems Inc., NeuroTrauma Sciences LLC, SyncThink Inc., Oxeia Biopharmaceuticals Inc., Oculogica Inc., Banyan Biomarkers Inc., Emotiv Inc., BioDirection Inc., and Neurologic Wellness Institute Product Innovation is the key trend gaining popularity in the concussion market. Major companies involved in the concussion market are focused on innovating new products to improve their observation power and sustain their position in the market. For Instance, In May 2022, TecTraum Inc., a US-based designer and developer of medical devices, and Nottingham-Spirk Design Associates Inc., a US-based product design firm, developed pro2cool, which is dedicated to providing the world's first point-of-care treatment for concussions and is the world's first-ever medical device treatment for concussions. The pro2cool® system is a revolutionary, noninvasive hypothermic treatment device that is intended to lessen the severity of concussion symptoms and allow patients to recover to their pre-injury baseline as quickly as possible. The gadget cools the head and neck locally, lowering blood temperature before it hits the brain. Previous clinical investigations found that chilling the brain within days following a concussion resulted in significant improvements in clinical results. In January 2020, Riverside Insights, a US-based provider of tools for clinical and educational standardized tests acquired ImPACT Applications Inc. for an undisclosed amount. Through this acquisition, riverside insights will gain the strategy of catalyzing growth by supporting the partnership of complementary businesses within the education and healthcare industries. Riverside and ImPACT Applications are both dedicated to providing schools and healthcare practitioners with comprehensive research-based evaluation solutions. ImPACT Applications Inc. is a US-based provider of testing technology solutions for concussion management practice. North America was the largest region in the concussion market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the concussion market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The concussion market consists of revenues earned by entities by providing concussion services such as consultations, diagnostic tests, imaging studies, CT scans, MRIs, and specialized diagnostic tests. The market value includes the value of related goods sold by the service provider or included within the service offering. The concussion market also includes sales of medications such as pain relievers, anti-nausea medication, or drugs targeting sleep disturbances or mood disorders. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The concussion market research report is one of a series of new reports from The Business Research Company that provides concussion market statistics, including the concussion industry's global market size, regional shares, competitors with a concussion market share, detailed concussion market segments, market trends and opportunities, and any further data you may need to thrive in the concussion industry. This concussion market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Glycomic therapeutics refers to the development of glycomics-based approaches in the field of therapeutics. Glycome is the complete set of glycans in a cell or organism, which is important for unraveling the complexity of biological systems and their implications for health and disease. Glycan plays important roles in various biological processes, including cell signaling, immune response, and disease development. The main glycomic therapeutics class types are isolated, and synthetic. Isolated glycomic therapy refers to the study or analysis of glycans in isolation, focusing specifically on the structural and functional characterization of individual glycan molecules and the therapeutic approach that involves the use of synthetic glycans or glycan-based molecules for the diagnosis and treatment of diseases or medical conditions. The various structures are glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins and heparin based glycans, targeting glycosphingolipids, others with various mode of actions such as inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin and enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1, 2 and 3, beta and gamma interferons, others. The various indications are thrombosis and chemoprophylaxis, anemia, anti-adhesive and anti-inflammatory, cataracts; Gaucher’s disease, mps-1 and IV, cancer, Alzheimer's disease, influenza type A and B, and others. The global glycomic therapeutics market is segmented - 1) By Class: Isolated, Synthetic 2) By Structures: Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins And Heparin Based Glycans, Targeting Glycosphingolipids, Other Structures 3) By Mode Of Action: Inhibits Neuraminidase, Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate, Erythropoietin And Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthase, Interleukin 1, 2 And 3, Beta And Gamma Interferons, Other Mode Of Action 4) By Indications: Thrombosis And Chemoprophylaxis, Anemia, Anti-Adhesive And Anti-Inflammatory, Cataracts, Gaucher’s Disease, Mps-1 And IV, Cancer, Alzheimer’s Disease, Influenza Type A And B, Other Indications The global glycomic therapeutics market size is expected to grow from $121.85 billion in 2022 to $141.31 billion in 2023 at a compound annual growth rate (CAGR) of 16.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of glycomic therapeutics market is expected to reach $255.71 billion in 2027 at a CAGR of 16.0%. The increase in the prevalence of diabetes is expected to drive the growth of the glycomic therapeutics market. Diabetes is a chronic medical condition that affects the body's ability to regulate blood sugar (glucose) levels. In diabetes, alterations in glycans have been observed, which can contribute to insulin resistance and other metabolic abnormalities. Specific glycan patterns serve as biomarkers for diagnosing diabetes, predicting its progression, and monitoring treatment responses. For instance, in May 2023, according to the report published by the National Center for Health Statistics, a U.S.-based government agency that provides statistical information to guide actions and policies to improve the public health of the American people, the percentage of diagnosed diabetes for adults aged 18 and over, United States increased from 9.3% in 2020 to 9.6% in 2021. Therefore, the increase in the prevalence of diabetes is driving the growth of the glycomic therapeutics market. Major players in the glycomic therapeutics market are F Hoffmann-La Roche Ltd., Bayer AG, Sanofi SA, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Merck KGaA, ICON plc, Agilent Technologies Inc., AMS Bio, Shimadzu Corporation, Waters Corporation, Bruker Corporation, BioMarin Pharmaceutical Inc., Bio Techne Corp., Promega Corporation, Halozyme Therapeutics Inc., Takara Bio Inc., Vector Laboratories, New England Biolabs Inc., Protalix Biotherapeutics Inc., Genovis AB, Ray Biotech Life Inc., IEC Group, Ludger Ltd, Z Biotech LLC, Alzheon Inc., and GlycoMar Limited Product innovation is a key trend gaining popularity in the glycomic therapeutics market. Major companies operating in the glycomic therapeutics sector are focused on developing new technological and innovative solutions to strengthen their position in the market. For instance, in April 2022, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company is discovering advanced therapies, launched a novel fixed-dose combination (FDC) of a DPP4 inhibitor (Dipeptidyl Peptidase 4 inhibitor), Teneligliptin, with Pioglitazone to improve glycemic control and to reduce insulin resistance in type 2 diabetes patients. In May 2022, Halozyme Therapeutics, a US-based biotechnology company, acquired Antares Pharma Inc. for $960 million. This purchase enhanced the pipeline portfolio of novel treatments employing its superior drug delivery methods, which have increased safety and efficacy, convenience, tolerability, and patient comfort and adherence. Antares Pharma Inc is a US-based pharmaceutical firm. North America was the largest region in the glycomic therapeutics in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glycomic therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the glycomic therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The glycomic therapeutics market consists of sales of investigational glycomic therapeutics and therapeutic glycomic that target glycans or glycan-related pathways for the diagnosis and treatment of diseases. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The glycomic therapeutics market research report is one of a series of new reports from The Business Research Company that provides glycomic therapeutics market statistics, including glycomic therapeutics industry global market size, regional shares, competitors with a glycomic therapeutics market share, detailed glycomic therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the glycomic therapeutics industry. This glycomic therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pompe disease is a genetic condition in which a complex sugar called glycogen accumulates in the body's cells. The situation is caused by a lack of an enzyme known as acid alfa glucosidase (GAA), which breaks down complex carbohydrates in the body. The main types of pompe disease are the classic infantile form, non-classic infantile form, late-onset form, and others. The classic infantile form of pompe disease is the most well-known, with significant heart dysfunction and obvious hypotonia beginning within a few months after birth. The various diagnosis includes blood test, genetic test, prenatal test, and other diagnosis. The treatment for pompe disease includes oral, parenteral, and others. The therapies for pompe disease are enzyme replacement therapy (ERT), substrate reduction therapy (SRT), gene therapy, and others that are used by hospitals or clinics, pharmaceuticals, researchers, others. The global pompe disease market is segmented - 1) By Type: Classic Infantile Form, Non-Classic Infantile Form, Late-Onset Form, Other Types 2) By Diagnosis: Blood Test, Genetic Test, Prenatal Test, Other Diagnosis 3) By Route of Administration: Oral, Parenteral, Other routes of administrations 4) By Therapy Type: Enzyme Replacement Therapy (ERT), Substrate Reduction Therapy (SRT), Gene Therapy, Other Therapies 5) By End Users: Hospitals / Clinics, Pharmaceuticals, Researchers, Other End-Users The global pompe disease market size is expected to grow from $1.56 billion in 2022 to $1.66 billion in 2023 at a compound annual growth rate (CAGR) of 6.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of pompe disease market is expected to reach $1.99 billion in 2027 at a CAGR of 4.5%. The increase in the prevalence of pompe disease is expected to propel the growth of the pompe disease market. Pompe disease, also known as glycogen storage disease type II or acid maltase deficiency, is a rare genetic disorder characterized by the build-up of glycogen (a complex sugar molecule) in various body tissues, particularly in muscles and organs. Treatments for pompe disease include protein replacement therapy, alglucosidase alfa, and Nexviazyme for intravenous infusion. A rise in pompe disease cases will contribute to the growth of the pompe disease market. For instance, in June 2022, according to the European Medicines Agency Highlights, a Europe-based intergovernmental organization, there are roughly 224 infantile-onset, 471 juvenile-onset, and 20,490 adult-onset persons in Europe with mutations that potentially cause Pompe disease based on the maximum birth incidence of 11.6 per 100,000. Therefore, the increase in the prevalence of pompe disease is driving the growth of the pompe disease market. Major players in the pompe disease market are F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Sanofi S.A., Thermo Fisher Scientific Inc., Fresenius Kabi AG, Danaher Corporation, Becton, Dickinson and Company, Astellas Pharma Inc., BioMérieux SA, BioMarin Pharmaceutical Inc., Nova Biomedical Corporation, Instrumentation Laboratory Company, Amicus Therapeutics Inc., Sekisui Diagnostics LLC, Spark Therapeutics Inc., Sangamo BioSciences Inc., Asklepios BioPharmaceutical Inc., Avrobio Inc., EKF Diagnostics Holdings plc, Trinity Biotech plc, Chembio Diagnostics Inc., Audentes Therapeutics Inc., Rougine Darou, Genethon, Maze Therapeutics Inc., Avidity Biosciences Inc., EpiVax Inc., M6P Therapeutics, Oxyrane UK Limited, and Valerion Therapeutics LLC. Product innovations are a key trend gaining popularity in the pompe disease market. Major companies operating in the pompe disease market are adopting innovations to sustain their position in the market. For instance, in March 2023, Amicus Therapeutics, a US-based biopharmaceutical company, announced the Pombiliti for enzyme replacement therapy (ERT). The European Commission approved this product as a long-term enzyme substitution treatment in combination with Miglustat for all adults living with late onset pompe disease. It is meant to be used with the oral enzyme stabilizer miglustat, the enzyme stabilizer component of AT-GAA, which has shown substantial improvements in muscles, joints, and respiratory measures during research trials. In December 2020, Bayer AG, a Germany-based pharmaceutical and biotechnology company, acquired Asklepios BioPharmaceutical Inc. for an undisclosed amount. This acquisition broadens, diversifies, and enriches Bayer's portfolio by adding an industry-leading adeno-associated virus (AAV)-based gene therapy platform to its portfolio, which has already demonstrated applicability across different therapeutic areas and includes a state-of-the-art gene therapy technology platform as well as an existing gene therapy manufacturing platform. Asklepios BioPharmaceutical Inc. is a US-based biopharmaceutical company specializing in developing, developing, and manufacturing gene therapies for operates in pompe disease. North America was the largest region in the pompe disease market in 2022. The regions covered in pompe disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pompe disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The pompe disease market includes revenues earned by entities by lumizyme, alglucosidase alfa, nexviazyme, and aval glucosidase alfa. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The pompe disease market research report is one of a series of new reports from The Business Research Company that provides pompe disease market statistics, including pompe disease industry global market size, regional shares, competitors with a pompe disease market share, detailed pompe disease market segments, market trends and opportunities, and any further data you may need to thrive in the pompe disease industry. This pompe disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Skin cancer diagnostics refers to the processes and methods healthcare professionals use to identify and determine the presence of skin cancer in individuals. These diagnostics typically involve a combination of clinical examination, imaging techniques, and laboratory tests to evaluate suspicious skin lesions and assess the extent and characteristics of the cancer. The main types of skin cancer diagnostics are basal cell carcinoma, squamous cell carcinoma, malignant melanoma, and others. Basal Cell Carcinoma is the most common form of skin cancer that arises from the basal cells of the skin's lower epidermis. The various types include diagnosis, therapeutics, that are widely applied in hospitals, clinics, laboratories, others. The global skin cancer diagnostics market is segmented - 1) By Cancer Type: Basal Cell Carcinoma, Squamous Cell Carcinoma, Malignant Melanoma, Other Cancer Types 2) By Type: Diagnosis, Therapeutics 3) By Application: Hospital, Clinic, Laboratory, Other Applications The global skin care diagnostics market size is expected to grow from $2.61 billion in 2022 to $2.85 billion in 2023 at a compound annual growth rate (CAGR) of 9.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of skin care diagnostics market is expected to reach $3.9 billion in 2027 at a CAGR of 8.1%. The increase in the incidence of melanoma is expected to propel the growth of the skin cancer diagnostics market going forward. Melanoma is a type of skin cancer that develops in the cells that produce melanin, the pigment responsible for skin color, hair, and eyes. Skin cancer diagnostics are crucial in identifying and characterizing skin lesions, aiding in early detection, accurate diagnosis, and effective treatment planning for skin cancer. For instance, in 2023, according to the report published by the American Cancer Society Inc., a US-based nationwide voluntary health organization dedicated to eliminating cancer, the number of male individuals suffering from melanoma in the United States increased from 57,180 in 2022 to 58,120 in 2023. Furthermore, in March 2023, according to the American Society of Clinical Oncology, a US-based professional organization representing all oncology physicians, melanoma accounts for around 1% of all skin cancers diagnosed in the United States. Yet, it is responsible for most skin cancer mortality. Melanoma is expected to kill 7,990 people in the United States in 2023 (5,420 males and 2,570 women). Melanoma killed a total of 57,043 people worldwide in 2020. Therefore, an increase in incidences of melanoma is driving the growth of the skin cancer diagnostics market. Major players in the skin cancer diagnostics market are Pfizer Inc., F. Hoffmann-La Roche Limited, Merck & Co., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Sanofi, Eli Lilly and Company, Canon Medical Systems Corporation, Amgen Inc., GE Healthcare, Daiichi Sankyo Company Limited., National Cancer Institute, Agilent Technologies Inc., bioMerieux SA, Teva Pharmaceutical Industries, Bruker Corp, Almirall, Genentech, Castle Biosciences, Sun Pharmaceutical Industries Limited., American Academy of Dermatology, Biolitec Ag, Alma Lasers, DermTech Inc., SkylineDx BV, DermLite LLC, and AMLo Biosciences Limited. Product Innovation is the key trend gaining popularity in the skin cancer diagnostics market. Major companies involved in the skin cancer diagnostics market are focused on innovating new products to improve their observation power and sustain their position in the market. For Instance, in May 2021, DermaSensor Inc., an Australia-based health technology company designing non-invasive tools, received FDA Breakthrough Device Designation for its DermaSensor device, an objective tool to assess lesions suggestive of skin cancer. It analyses and provides feedback on the cellular substructure, which is undetectable to the human eye even when aided by a dermatoscopy, and the ability to do so in seconds can assist healthcare providers during the critical period of patient assessment and medical decision-making. In August 2022, Bristol Myers Squibb, a US-based biopharmaceutical company, acquired Turning Point Therapeutics Inc. for an undisclosed sum. This acquisition broadens, diversifies, and enriches Bristol's portfolio by adding a pipeline of investigational medicines designed to target the most frequent oncogenic mutations, including repotrectinib. Turning Point Therapeutics, Inc., is a US-based pharmaceutical company that provides targeted therapies for breast, ovarian, melanoma cancer treatment. North America was the largest region in the skin cancer diagnostics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in skin cancer diagnostics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the skin cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The skin cancer diagnostics market consists of revenues earned by entities by providing skin cancer diagnostics services such as diagnostic tests, visual inspection, dermoscopy, biopsy, imaging techniques (ultrasound, CT scan, MRI), laboratory tests (immunohistochemistry, molecular testing, genetic analysis). The market value includes the value of related goods sold by the service provider or included within the service offering. The skin cancer diagnostics market also includes sales of dermatoscope, biopsy tools, imaging equipment (ultrasound, CT scanners, MRI machines), molecular testing kits, immunohistochemistry (IHC) kits, laboratory analysis software. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The skin cancer diagnostics market research report is one of a series of new reports from The Business Research Company that provides skin cancer diagnostics market statistics, including skin cancer diagnostics industry global market size, regional shares, competitors with skin cancer diagnostics market share, detailed skin cancer diagnostics market segments, market trends, and opportunities, and any further data you may need to thrive in the skin cancer diagnostics industry. This skin cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

ADME toxicology testing is a set of studies conducted to assess the potential toxicity of a substance or drug candidate based on its absorption, distribution, metabolism, and excretion (ADME) properties. These tests are used in drug development to ensure the well-being of individuals exposed to substances. The main products of ADME toxicology testing are instruments, software solutions, assay systems, reagents, and others. Instruments refer to devices or tools that are designed and used for a specific purpose, often in scientific, medical, or technical contexts. It is used in ADME toxicity testing for measuring and analyzing the readings. The methods used are cellular assay, biochemical assay, in silica, and ex-vivo, by accompanying technologies such as, sing cell culture, high throughput, molecular imaging, omics technology, and other technologies. It is applied for systemic toxicity, renal toxicity, hepatotoxicity, neurotoxicity, and others by cosmetics and household products, pharmaceutical industry, animal industry, food industry, and others. The global ADME toxicology testing market is segmented - 1) By Product Type: Instruments, Software Solutions, Assays Systems, Reagents, Other Products 2) By Method: Cellular Assay, Biochemical Assay, In Silica, Ex-vivo 3) By Technology: Cell Culture, High Throughput, Molecular Imaging, OMICS Technology, Other Technologies 4) By Application: Systemic Toxicity, Renal Toxicity, Hepatotoxicity, Neurotoxicity, Other Applications 5) By End-User: Cosmetics And Household Products, Pharmaceutical Industry, Animal Industry, Food Industry, Other End Users The global ADME toxicology testing market size is expected to grow from $8.37 billion in 2022 to $9.30 billion in 2023 at a compound annual growth rate (CAGR) of 11.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of ADME toxicology testing market is expected to reach $14.05 billion in 2027 at a CAGR of 10.9%. The rising demand for novel drugs is expected to propel the growth of the ADME toxicology testing market going forward. Novel drugs are pharmaceutical substances that have not been previously approved or marketed for therapeutic use. ADME toxicity testing is a major step in drug development to ensure that the novel drug is safe and doesn’t produce any harmful toxins in the body. For instance, according to the US Food and Drug Administration, a US-based health regulatory authority approved 53 novel drugs in 2020, compared to 48 drugs in the previous year. Therefore, the rising demand for novel drugs is driving the growth of the ADME toxicology testing market. Major players in the ADME toxicology testing market are AbbVie Inc., Thermo Fisher Scientific Inc., Boehringer Ingelheim GmbH, Laboratory Corporation of America Holdings, Corning Incorporated, Eurofins Scientific SE, Agilent Technologies Inc., Lonza Group AG, Dassault Systèmes SE, Catalent Inc., Charles River Laboratories International Inc., Beckman Coulter Inc., PerkinElmer Inc., Bio-Rad Laboratories Inc., Curia Global Inc, Promega Corporation, Takara Bio Inc, AB Sciex LLC, QPS Holdings LLC, Simulations Plus Inc., Cyprotex, XenoTech LLC, BioIVT LLC, Absorption Systems, Creative Bioarray, SOLVO Biotechnology Rt., Creative Biolabs Inc, Gentronix Limited, Admecell Inc., and Molecular Discovery Ltd. Technological advancements are a key trend gaining popularity in the ADME toxicology testing market. Major companies operating in the ADME toxicology testing market are introducing innovative assay solutions based on advanced technologies such as Logica to sustain their position in the market. For instance, in April 2022, Charles River Laboratories International Inc., a US-based pharmaceutical company, and Valo Health Inc., a US-based AI-health solution company, launched Logica, an AI-based drug development solution. The new solution leverages Valo’s AI-powered Opal Computational Platform to provide users with ADME toxicology testing services and other drug delivery solutions. In September 2022, BioIVT, a US-based drug development solutions provider, acquired XenoTech for an undisclosed amount. The acquisition completes the product portfolio of BioIVT and helps it expand its product offerings in newer geographies and to a broader customer base. XenoTech is a US-based contract research organization providing ADME-toxicology testing services. North America was the largest region in the ADME toxicology testing market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in ADME toxicology report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the ADME toxicology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The ADME toxicology testing market consists of revenues earned by entities by providing services such as drug discovery research, measuring gene expression, and preclinical efficacy testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The ADME toxicology testing market also includes sales of ADMET predictors, and UV spectrophotometers, which are used in providing ADME toxicology testing services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The ADME toxicology testing market research report is one of a series of new reports from The Business Research Company that provides ADME toxicology testing market statistics, including ADME toxicology testing industry global market size, regional shares, competitors with an ADME toxicology testing market share, detailed ADME toxicology testing market segments, market trends and opportunities, and any further data you may need to thrive in the ADME toxicology testing industry. This ADME toxicology testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Autism spectrum disorder (ASD) treatment is medication for a neurodevelopmental disorder affecting communication, behavior, and social interaction. Autism spectrum disorder (ASD) treatment includes behavior therapy, speech-language therapy, and play-based therapy, which improve a person's comprehension and use of speech and language. The main therapies of autism spectrum disorders treatment are antipsychotic drugs; SSRIs or antidepressants, stimulants, sleep medications, and other drug therapies. Antipsychotic drugs are used to treat the symptoms related to schizophrenia and other psychotic conditions. The treatment of autism spectrum disorders includes behavioral approaches, early intervention, and medication that are used to treat autistic disorder, asperger syndrome, pervasive developmental disorder, and others. These treatment products are sold in hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. The global autism spectrum disorders treatment market is segmented - 1) By Drug Therapy: Antipsychotic Drugs, SSRIs or Antidepressants, Stimulants, Sleep Medications, Other Drug Therapies 2) By Treatment Approach: Behavioral Approaches, Early Intervention, Medication 3) By Application: Autistic Disorder, Asperger Syndrome, Pervasive Developmental Disorder, Other Applications 4) By Distribution Channel: Hospital Pharmacies, Drug Stores and Retail Pharmacies, Online Pharmacies The global autism spectrum disorders treatment market size is expected to grow from $2.55 billion in 2022 to $2.72 billion in 2023 at a compound annual growth rate (CAGR) of 6.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of autism spectrum disorders treatment market is expected to reach $3.47 billion in 2027 at a CAGR of 6.3%. The increasing prevalence of autism spectrum disorders (ASD) is expected to propel the growth of the autism spectrum disorders market going forward. Autism spectrum disorders encompass various medical conditions distinguished by challenges in social interaction and communication skills to varying degrees. The rise in the number of children identified with ASDs plays a crucial role in developing various treatment options for children with ASDs. For instance, according to the Centers for Disease Control and Prevention (CDC), a US-based national public health agency, one in 38 children aged eight years had autism spectrum disorders in 2020 in the USA, where autism spectrum disorders are 3.8 times more prevalent in boys than girls. Therefore, the increasing prevalence of ASDs will fuel the growth of the autism spectrum disorders treatment market. Major players in the autism spectrum disorders treatment market are Pfizer Inc., Johnson & Johnson Services Inc., Roche Holding AG, Novartis AG, Bristol-Myers Squibb, Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Zenotech Laboratories Limited, Jazz Pharmaceuticals plc, Alembic Pharmaceuticals Limited, 4D Pharma plc, Acadia Pharmaceuticals Inc., Impel Pharmaceuticals Inc, Enterin Inc., Cognoa, BrainStorm Cell Therapeutics Inc., Axial Therapeutics Inc., Neurim Pharmaceuticals Inc., Curemark LLC, Yamo Pharmaceuticals LLC, Zynerba Pharmaceuticals Inc., Pax Medica, Stalicla SA, Neurotech International Limited, Confluence Pharmaceuticals LLC, MapLight Therapeutics Inc., SciSparc Ltd., Q BioMed Inc., Mercy Care, and IAMA Therapeutics. Technology innovation in autism spectrum disorder treatment has emerged as a key trend gaining popularity in the autism spectrum disorders market. Researchers are focusing their efforts on creating innovations in behavioral analysis of autism patients, which helps in developing social and occupational skills in children with autism. For instance, in December 2021, BrainCo Inc, a US-based company, introduced a new autism intervention method based on brain-computer interface technology through clinical trials with China Autism Rehabilitation Center, Shanghai Children’s Hospital, and Beijing Children’s Hospital. This novel method combines a non-invasive EEG headband with computer-based games, activities, and exercises that allow the therapists to understand new patterns of individuals’ real-time brain activity, track their progress by observing their interaction with others, and understand their facial expressions by analyzing eye contact. In December 2022, MBF Healthcare Partners II, L.P., a US-based healthcare-focused middle-market private equity firm, acquired ABA Connect for an undisclosed amount. With this acquisition, Healthcare Partners II, L.P., will expand ABI Connect’s services to children and families throughout Texas and other states in the USA. ABA Connect is a US-based applied behavior analysis provider that uses evidence-based principles to help enhance the quality of life for children and families affected by autism spectrum disorders. North America was the largest region in the autism spectrum disorders treatment market in 2022. The regions covered in autism spectrum disorders treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the autism spectrum disorders treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The autism spectrum disorders treatment market involves revenues earned by entities by providing therapies, assistive technologies, behavioral interventions, and education programs for treating and managing autism spectrum disorders (ASD). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The autism spectrum disorders treatment market research report is one of a series of new reports from The Business Research Company that provides autism spectrum disorders treatment market statistics, including the autism spectrum disorders treatment industry's global market size, regional shares, competitors with an autism spectrum disorders treatment market share, detailed autism spectrum disorders treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the autism spectrum disorders treatment industry. This autism spectrum disorders treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Cardiometabolic diseases refer to a group of interconnected health conditions that impact both the cardiovascular and metabolic systems. These diseases often occur together and share common risk factors, such as obesity, physical inactivity, an unhealthy diet, and genetic predisposition. The main types of cardiometabolic diseases are chronic or congestive heart failure, hypertension, type 2 diabetes, and obesity. Congestive heart failure refers to a chronic condition in which the heart's ability to pump blood efficiently is compromised. The various treatments include ACE inhibitors, diuretics, glucophage, liposuction, and other treatments. The various dosages include tablets, injections, and various routes of administration including oral, intravenous, and others that are used by various end-users such as clinics, hospitals, and others. The global cardiometabolic diseases market is segmented - 1) By Type: Chronic/Congestive Heart Failure, Hypertension, Type 2 Diabetes, Obesity 2) By Treatment: ACE inhibitors, Diuretics, Glucophage, Liposuction, Other Treatments 3) By Dosage: Tablet, Injection 4) By Route Of Administration: Oral, Intravenous, Other Routes Of Administration 5) By End-Users: Clinic, Hospital, Other End-Users The global cardiometabolic diseases market size is expected to grow from $101.59 billion in 2022 to $106.30 billion in 2023 at a compound annual growth rate (CAGR) of 4.64%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of cardiometabolic diseases market is expected to reach $123.28 billion in 2027 at a CAGR of 3.77%. A high rate of obesity is expected to propel the growth of the cardiometabolic disease market going forward. Obesity is a complex condition characterized by the excessive accumulation of body fat, leading to higher body weight. Obesity directly influences the occurrence of cardiovascular risk factors such as dyslipidemia, type 2 diabetes, hypertension, and sleep problems. For instance, in March 2022, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organization, over 1 billion individuals are affected by obesity globally, which included 340 million teenagers, 650 million adults, and 39 million kids each year. By 2025, the WHO predicts that 167 million adults and children are going to lose some of their health due to being overweight or obese. Therefore, the high rate of obesity is driving the growth of the cardiometabolic diseases market. Major players in the cardiometabolic diseases market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Kowa Company Ltd., Thermo Fisher Scientific, Abbott Laboratories, Takeda Pharmaceutical Company, Eli Lilly and Company, Novo Nordisk A/S, Siemens Healthineers, Boehringer Ingelheim International GmbH, Becton, Dickinson and Company, Stryker Corporation, AstraZeneca Plc, Viatris Inc., Biocrates Life Sciences AG, Boston Scientific, Astellas Pharma Inc., Terumo Corporation, Agilent Technologies, Edwards Lifesciences, Bruker Corporation, Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., and Cardax Inc. The adoption of advanced technologies is a key trend gaining popularity in the cardiometabolic diseases market. Companies involved in the market for cardiometabolic diseases are working on adopting novel technologies to sustain their position in the market. For instance, in February 2023, Eko Health Inc., a US-based inventor of heart and lung disease-detecting digital health technologies, launched the Sensora cardiac disease detection platform. It includes artificial intelligence (AI) that reliably detects structural murmurs, a symptom of valvular heart disease (VHD), and care pathway analytics software that provides metrics and downstream insight into the patient journey through the healthcare system. This digital stethoscope is used to capture and analyze electrical impulses and heartbeats. In December 2021, Novo Nordisk, a Denmark-based global healthcare company, acquired Dicerna Pharmaceuticals for an amount of $3.3 billion. The acquisition helped Novo Nordisk's strategy of developing and applying a broad range of technology platforms across all therapeutic areas. Dicerna Pharmaceuticals is a US-based biopharmaceutical company. North America was the largest region in the cardiometabolic diseases market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiometabolic diseases market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the cardiometabolic diseases market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The cardiometabolic diseases market consists of revenues earned by entities by providing services such as non-invasive CAD testing, cardio-preventive care, behavioral counseling, and clinical assessment. The market value includes the value of related goods sold by the service provider or included within the service offering. The cardiometabolic diseases market also includes sales of medications, blood glucose monitoring devices, blood pressure monitors, cholesterol testing kits, and weight management products used to provide cardiometabolic diseases services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The cardiometabolic diseases market research report is one of a series of new reports from The Business Research Company that provides cardiometabolic diseases market statistics, including cardiometabolic diseases industry global market size, regional shares, competitors with a cardiometabolic diseases market share, detailed cardiometabolic diseases market segments, market trends, and opportunities, and any further data you may need to thrive in the cardiometabolic diseases industry. This cardiometabolic diseases market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Health economics and outcomes research (HEOR) services refer to a specialized field within healthcare that utilizes economic and epidemiological methods to assess the clinical and financial outcomes of healthcare interventions. HEOR services evaluate the cost-effectiveness, safety, and real-world impact of medical treatments, interventions, and healthcare policies. The main types of health economics and outcomes research (HEOR) services are real-world evidence, payer evidence, pricing and reimbursement, epidemiology studies, market access, and others. Real-world evidence (RWE) refers to data collected from real-world settings, such as electronic health records, claims databases, and patient registries, to generate insights on treatment effectiveness, safety, and patient outcomes. The HEOR service is either outsourced or offered in-house by service providers such as consultancies and contract research organizations (CROs) for end-users, including healthcare providers, healthcare payers, biotechnology and pharmaceutical companies, government organizations, and others. The global health economics and outcomes research (HEOR) services market is segmented - 1) By Service: Real World Evidence, Payer Evidence, Pricing And Reimbursement, Epidemiology Studies, Market Access, Other Services 2) By Offering: Outsourced, In-House 3) By Service Provider: Consultancy, Contract Research Organizations (CRO) 4) By End-Use: Healthcare Provider, Healthcare Payers, Biotechnology And Pharmaceutical Companies, Government Organization, Other End-Users The global health economics and outcomes research (HEOR) services market size is expected to grow from $1.22 billion in 2022 to $1.38 billion in 2023 at a compound annual growth rate (CAGR) of 13.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The size of health economics and outcomes research (HEOR) services market are expected to reach $2.18 billion in 2027 at a CAGR of 12.1%. The surge in the number of clinical trials is expected to propel the growth of the health economics and outcomes research services market going forward. Clinical trials are research studies conducted with human participants to evaluate the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures. Health economics and outcomes research (HEOR) services are utilized in clinical trials to evaluate medical interventions' economic impact, cost-effectiveness, and real-world outcomes, providing valuable insights for decision-making and reimbursement strategies. For instance, in May 2023, according to the United States National Library of Medicine, the number of clinical trials registered studies increased from 399,499 in 2022 to 437,533 in all 50 states and across 221 countries. Moreover, it was reported that 140,492 studies (31%) are registered in the U.S. only, while 241,498 studies (53%) are recorded in non-U.S. locations. Therefore, the surge in the number of clinical trials is driving the growth of the health economics and outcomes research services market. Major players in the health economics and outcomes research (HEOR) services market are McKesson Corporation, Optum Inc., Cardinal Health, IQVIA Inc., ICON PLC, PPD Inc., Syneos Health, Medlior Health Outcomes Research Ltd., Axtria Inc., Parexel International, RTI Health Solutions, Wellth Inc., Westat, SidekickHealth, Analysis Group, Carelon Research, Precision Health Economics, Avalon Health Economics LLC, Lumanity Inc., Pharmerit BV, Epistemix Inc., Crowdcuring, DocME, and Bohn Epidemiology LLC. Advancements in real-world evidence platforms are a key trend gaining popularity in the health economics and outcomes research (HEOR) services market. Major companies operating in the health economics and outcomes research services market are adopting innovative technologies to transform healthcare decision-making, drug development, and patient care by leveraging real-world data to generate evidence-based insights and sustain their position in the market. For instance, in April 2023, Komodo Health, a US-based healthcare technology company specializing in real-world evidence (RWE) and data analytics, launched MapEnhance, a network of specialty data partners integrated into real-world evidence (RWE) technology platform. The new platform enhances the analytical capabilities of Komodo's Healthcare Map by incorporating exclusive and highly informative data curated from its partner network. MapEnhance empowers customers with a comprehensive and detailed real-world perspective on clinical events and patient populations, enabling unprecedented insight. In January 2023, SCIRIS, a UK-based company engaged in healthcare communications and compliance solutions, acquired Source Health Economics for an undisclosed amount. With this acquisition, SCIRIS enhances its capabilities in providing comprehensive health economics and outcomes research (HEOR) services to its global clients, empowering them to achieve success throughout all stages of brand development. Source Health Economics is a UK-based HEOR consulting company engaged in health technology assessment, statistics, health economics, and medical writing. North America was the largest region in the health economics and outcomes research (HEOR) services market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in health economics and outcomes research (HEOR) services report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the health economics and outcomes research (HEOR) services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The health economics and outcomes research (HEOR) services market includes revenues earned by entities by providing economic modeling, health outcomes assessment, and comparative effectiveness research services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The health economics and outcomes research (HEOR) services market research report is one of a series of new reports from The Business Research Company that provides health economics and outcomes research (HEOR) services market statistics, including the health economics and outcomes research (HEOR) services industry's global market size, regional shares, competitors with a health economics and outcomes research (HEOR) services market share, detailed health economics and outcomes research (HEOR) services market segments, health economics and outcomes research (HEOR) services market trends and opportunities, and any further data you may need to thrive in the health economics and outcomes research (HEOR) services industry. This health economics and outcomes research (HEOR) services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.